In the early 1960s, the pharmaceutical company William S. Merrell distributed thousands of unlabeled doses of thalidomide to doctors across the United States, who were told it was safe for treating various conditions, including insomnia and morning sickness. Unbeknownst to the patients, including pregnant women, the drug would cause severe birth defects, such as phocomelia, a rare condition characterized by shortened limb deformities. Many children born with these deformities are now adults, seeking recognition and support from the US government.
Dr. Frances Oldham Kelsey, a medical reviewer at the FDA, played a crucial role in preventing the widespread approval of thalidomide in the US. Her actions led to significant changes in the agency's testing and approval process, resulting in the robust regulations that exist today. However, despite Kelsey's efforts, thousands of US patients, including pregnant women, were already exposed to the drug. President John F. Kennedy publicly praised Kelsey for preventing a "terrible human tragedy" in the US, but many thalidomide survivors argue that the government has downplayed the extent of the problem.
Gwen Riechmann, a thalidomide survivor born with phocomelia, is one of many who are pushing for recognition and support. She co-founded the advocacy group USA Thalidomide Survivors in 2018, which represents around 100 people, including survivors and allies. The group is advocating for Congress to pass a bill that would officially acknowledge American thalidomide survivors and provide each with $150,000, with the possibility of additional support in the future.
According to Jennifer Vanderbes, author of the book Wonder Drug, which details the history of thalidomide, the company did not require doctors to track the medication or report side effects. This lack of oversight led to a significant number of unaccounted-for doses of thalidomide, making it difficult to determine the exact number of survivors. John Swann, a retired FDA senior historian, agrees that the number of survivors is likely higher than the 17 formally acknowledged by the FDA.
Thalidomide survivors face significant health challenges as they age, and many are seeking urgent support. Riechmann and others argue that the US government has a responsibility to acknowledge and support its citizens who were affected by the drug. The advocacy group USA Thalidomide Survivors estimates that there could be around 100 US survivors, and they are pushing for recognition and support.
The thalidomide scandal has had a lasting impact on the FDA's testing and approval process, with many considering it a turning point in the regulation of pharmaceuticals. Vanderbes notes that thalidomide is "probably the most iconic toxic drug of all time" due to its signature injuries. The scandal has also led to increased awareness of the importance of rigorous testing and oversight in the pharmaceutical industry.
As the number of thalidomide survivors continues to grow, advocacy groups are pushing for swift action from Congress. With survivors aging and their health deteriorating, the need for recognition and support is becoming increasingly urgent. The US government is yet to provide any significant support or recognition to its thalidomide survivors, making it the only country that has not taken action.
Key points
- The US government is accused of downplaying the number of thalidomide survivors, with many still seeking recognition and support today.
- Thalidomide survivors are pushing for Congress to pass a bill that would officially acknowledge American thalidomide survivors and provide each with $150,000.
- The thalidomide scandal has had a lasting impact on the FDA's testing and approval process, leading to increased awareness of the importance of rigorous testing and oversight in the pharmaceutical industry.
